Please login to the form below

Not currently logged in

Voltarra names new CEO

Richard Becker has experience at Alcon, Merck, Novartis, OSI, Bayer and BASF

Voltarra Pharmaceuticals has appointed Richard Becker as CEO.

Becker brings more than 20 years' experience to the US biopharma, including senior commercial roles at Alcon, Merck, Novartis, OSI, Bayer and BASF.

In his new role, he leads a company with a pipeline of drugs for rheumatology, central nervous system oncology and immunology.

Voltarra's lead product is VOLT01, which is in late-stage trials for the treatment of osteoarthritis.

Becker said: “The broad portfolio will allow Voltarra Pharmaceuticals to capitalise on development synergies and favourably position the company with external customers. We are extremely excited about the pipeline as well as future plans for a partner in taking VOLT01 to the next stage.”

19th November 2013

From: Sales


Featured jobs

Subscribe to our email news alerts


Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?